Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates
Autore:
Harker, LA; Marzec, UM; Kelly, AB; Chronos, NRF; Sundell, IB; Hanson, SR; Herbert, JM;
Indirizzi:
Emory Univ, Sch Med, Div Hematol & Oncol, Dept Med, Atlanta, GA 30322 USA Emory Univ Atlanta GA USA 30322 & Oncol, Dept Med, Atlanta, GA 30322 USA Emory Univ, Sch Med, Yerkes Reg Primate Res Ctr, Atlanta, GA 30322 USA Emory Univ Atlanta GA USA 30322 eg Primate Res Ctr, Atlanta, GA 30322 USA Sanofi Rech, F-31036 Toulouse, France Sanofi Rech Toulouse France F-31036 anofi Rech, F-31036 Toulouse, France
Titolo Testata:
CIRCULATION
fascicolo: 22, volume: 98, anno: 1998,
pagine: 2461 - 2469
SICI:
0009-7322(199812)98:22<2461:CIOSGA>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLATELET ADENYLATE-CYCLASE; MONOCLONAL-ANTIBODIES; TICLOPIDINE; ADP; THROMBOSIS; ANTIPLATELET; PREVENTION; BINDING; BABOONS; STROKE;
Keywords:
clopidogrel; thrombus; stents; aspirin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Harker, LA Emory Univ, Sch Med, Div Hematol & Oncol, Dept Med, 1639 PierceDr,WMB Room Emory Univ 1639 Pierce Dr,WMB Room 1003 Atlanta GA USA 30322 om
Citazione:
L.A. Harker et al., "Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates", CIRCULATION, 98(22), 1998, pp. 2461-2469

Abstract

Background-A recent study showed that clopidogrel reduces thrombo-occlusive complications in patients with symptomatic atherosclerosis more effectively than aspirin. Methods and Results-The effects of clopidogrel and aspirin have been compared, singly and in combination, for measurements of In-111-labeled platelets and I-125-labeled fibrin deposition in baboon models of arterial thrombosis and related to platelet aggregation and expression of activation epitopes induced by ADP, collagen, and thrombin receptor agonist peptide (TRAP) and to template bleeding times (BTs). Low-dose oral clopidogrel (0.2 mg.kg(-1).d(-1)) produced cumulative (1) intermediate decreases in In-111-platelet and I-125-fibrin deposition for segments of prosthetic vascular graft, deployed endovascular metallic stents, and endarterectomized aorta (P<0.009 in all cases); (2) elimination of ADP-induced platelet aggregation (P<0.001); (3) modest inhibition of collagen-induced platelet aggregation (P<0.01); (4) no reduction in TRAP-induced platelet aggregation; and (5) minimal prolongation of BTs (P=0.03). High-dose oral clopidogrel (greater than or equal to 2 mg/kg) produced the same effects within 3 hours. The effects of clopidogrel dissipated over 5 to 6 days. Aspirin 10 mg.kg(-1).d(-1) alone did not decrease In-111-platelet and I-125-fibrin deposition on segments of vascular graft but detectably decreased In-111-platelet and I-125-fibrin accumulation on stents (P<0.01), minimally inhibited ADP- and collagen-induced platelet aggregation (P<0.05 in both cases), and minimally prolonged BTs (P=0.004). Within 3 hours of aspirin administration, the antithrombotic effects ofacute high-dose or chronic low-dose clopidogrel were substantially enhanced, and BTs were modestly prolonged without inhibiting platelet aggregation induced by TRAP (P<0.001 in all cases compared with clopidogrel alone). Conclusions-Clopidogrel produces irreversible, dose-dependent, intermediate reduction in thrombosis that is substantially enhanced by the addition ofaspirin. The effects of combining aspirin and clopidogrel need to be evaluated in patients at risk of vascular thrombosis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/09/20 alle ore 09:08:13